Tag: CPI-0610

January 3, 2019

Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an...
October 11, 2018

Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several...